Noxopharm Ltd. (AU:NOX)
ASX:NOX
Want to see AU:NOX full AI Analyst Report?
Top Page
Noxopharm Ltd.
(Sydney:NOX)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.08
▼(-6.67% Downside)
Action:Reiterated
Date:05/27/26
The score is primarily constrained by weak financial performance (large ongoing losses, heavy cash burn, and a weaker 2025 balance sheet with higher leverage). Technicals provide some support via a price above major moving averages, but overbought RSI and slightly negative MACD reduce confidence. Valuation is also penalized by negative earnings and no dividend yield.
Positive Factors
Oncology R&D focus
A dedicated oncology and immunotherapy R&D focus aligns with durable, secular demand for improved cancer treatments. This strategic specialization supports long-term relevance, potential partnerships or licensing, and positions the company to capture value if clinical programs progress.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow across years creates a structural financing need. Ongoing cash burn forces reliance on external funding, increasing dilution risk, constraining R&D timelines, and limiting the company's ability to execute multi-year clinical programs independently.
Read all positive and negative factors
Positive Factors
Negative Factors
Oncology R&D focus
A dedicated oncology and immunotherapy R&D focus aligns with durable, secular demand for improved cancer treatments. This strategic specialization supports long-term relevance, potential partnerships or licensing, and positions the company to capture value if clinical programs progress.
Read all positive factors
Noxopharm Ltd. (NOX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$27.04M
Dividend YieldN/A
Average Volume (3M)123.50K
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue GrowthN/A
EPS Growth-137.97%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding307,237,950
10 Day Avg. Volume89,571
30 Day Avg. Volume123,503
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)22.89
Price to Sales (P/S)5.60
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Noxopharm Ltd. Business Overview & Revenue Model
Company Description
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherap...
How the Company Makes Money
null...
Noxopharm Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
32
Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.82M | 2.40M | 6.01M | 5.43M | 5.61M |
| Gross Profit | -1.45M | -534.81K | 5.86M | 5.17M | 5.35M |
| EBITDA | -5.38M | -5.95M | -20.85M | -23.70M | -5.85M |
| Net Income | -4.88M | -3.58M | -15.06M | -18.67M | -9.35M |
Balance Sheet | |||||
| Total Assets | 4.58M | 6.78M | 10.13M | 26.59M | 47.85M |
| Cash, Cash Equivalents and Short-Term Investments | 1.55M | 2.32M | 3.01M | 14.01M | 26.80M |
| Total Debt | 2.48M | 0.00 | 0.00 | 160.62K | 349.31K |
| Total Liabilities | 3.89M | 1.29M | 1.06M | 2.48M | 7.08M |
| Stockholders Equity | 689.96K | 5.50M | 9.07M | 24.12M | 40.78M |
Cash Flow | |||||
| Free Cash Flow | -5.82M | -684.31K | -10.95M | -13.73M | -8.85M |
| Operating Cash Flow | -5.82M | -684.31K | -10.95M | -13.73M | -8.85M |
| Investing Cash Flow | 2.48M | 0.00 | 123.51K | 0.00 | 225.23K |
| Financing Cash Flow | 2.60M | 0.00 | -178.09K | 975.73K | 28.32M |
Noxopharm Ltd. Technical Analysis
Positive
0.09
Price Trends
0.07
Positive
0.07
Positive
0.08
Positive
Market Momentum
<0.01
Negative
74.40
Negative
85.71
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NOX, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.08, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 74.40 is Negative, neither overbought nor oversold. The STOCH value of 85.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NOX.
Noxopharm Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$27.99M | 10.29 | 10.35% | 2.81% | -18.17% | -70.18% | |
52 Neutral | AU$78.86M | -8.83 | -62.49% | ― | ― | -13.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$27.04M | -4.58 | 2509.60% | ― | ― | -137.97% | |
45 Neutral | AU$5.32M | -0.22 | 2844.96% | ― | ― | 62.07% | |
44 Neutral | AU$85.82M | -10.71 | -40.65% | ― | -100.00% | -11.11% | |
41 Neutral | AU$161.94M | -5.26 | 279.21% | ― | ― | -37.23% |
* Healthcare Sector Average
AU:NOX
Noxopharm Ltd.
0.09
0.01
19.44%
AU:PTX
Prescient Therapeutics Limited
0.08
0.03
65.96%
AU:CHM
Chimeric Therapeutics Ltd.
0.10
-0.07
-41.18%
AU:EZZ
EZZ Life Science Holdings Ltd.
0.63
-0.89
-58.61%
AU:RCE
Recce Pharmaceuticals Ltd.
0.55
0.21
59.42%
AU:ALA
Arovella Therapeutics Limited
0.07
>-0.01
-5.33%
Noxopharm Ltd. Corporate Events
Noxopharm Showcases Potent New TLR8-Based Immuno-Oncology Platform
May 25, 2026
Noxopharm Limited unveiled new data demonstrating how its Sofra technology platform can significantly amplify Toll-like receptor 8 activity, a key immune sensor being targeted in cancer therapy. The company’s proprietary oligonucleotides sho...
Noxopharm Plans CEO Option Grant Tied to Long-Term Share Price Growth
May 8, 2026
Noxopharm Ltd. has notified the ASX of a proposed issue of up to 2 million new options to its chief executive officer, with an exercise price set at a 25% premium and an expiry date of 15 April 2030. The options, forming a new class of securities,...
Noxopharm Taps Novotech to Advance SOF-SKN Toward Key FDA Milestone
May 5, 2026
Noxopharm has engaged global clinical research organisation Novotech to support preparations for a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for its SOF-SKN candidate, part of the Sofra technology platform. Th...
Noxopharm Data Backs SOF-16’s Anti-Inflammatory Potential in Autoimmune Disease
Apr 30, 2026
Noxopharm has reported new data demonstrating the potential of its Sofra platform, showing that SOF-16, the active ingredient in its SOF-SKN cutaneous lupus candidate, exhibits strong anti-inflammatory effects in vitro on samples from patients wit...
Noxopharm Names CFO Shawn van Boheemen as New Company Secretary
Apr 29, 2026
Noxopharm Limited has appointed Chief Financial Officer Shawn van Boheemen as Company Secretary, effective immediately, following the resignation of long-serving secretary David Franks. The company highlighted van Boheemen’s three decades of...
Noxopharm deepens Sofra push with Tezcat deal, CEO shift and key trial progress
Apr 23, 2026
Noxopharm has strengthened its positioning in immunology drug development by signing a memorandum of understanding with U.S.-based Tezcat Biosciences to explore combining Sofra RNA assets with Tezcat’s targeted drug delivery system, aiming t...
Noxopharm’s SOF-SKN shows prolonged skin retention in preclinical study
Apr 21, 2026
Noxopharm Limited has reported new preclinical pharmacokinetic data for its cutaneous lupus candidate SOF-SKN, showing that the active ingredient SOF-16 has a skin half-life of about 3.5 days in both normal and disease-like tissue. The long reside...
Noxopharm Tightens Disclosure Controls After CEO Resigns and Director Notices Updated
Apr 14, 2026
Noxopharm has detailed changes in director interests following the resignation of Managing Director and CEO Dr Gisela Mautner on 14 April 2026, including the lodgement of a Final Director’s Interest Notice and a delayed Change of Director...
Noxopharm CEO Resigns as Biotech Awaits Successor Amid Strategic Shift
Apr 14, 2026
Noxopharm Limited, a clinical-stage Australian biotech specialising in cancer and inflammation therapies and mRNA safety-enhancing technologies, develops proprietary drugs through its Sofra and Chroma platforms in collaboration with specialist in-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.